Esperion Therapeutics, Inc. Announces Oral Presentation On ETC-1002 At 2013 Scientific Sessions Of The American Heart Association
Published: Nov 12, 2013
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation session by principal investigator Paul D. Thompson, M.D., on November 18 at the 2013 Scientific Sessions of the American Heart Association in Dallas. Later in the day, the Company will webcast a briefing of the results.
Help employers find you! Check out all the jobs and post your resume.